Pharma Giants Merck and Pfizer Underperform Broader Market Amid Mixed Earnings Season

While the S&P 500 and Nasdaq geared up for modest upside on a recent Tuesday trading session, two pharmaceutical behemoths moved distinctly against the grain. Merck’s shares retreated 1%, with Pfizer’s stock tumbling nearly 5%—a pronounced divergence that underperform the overall rally. This weakness from industry titans raises important questions about the health of the pharmaceutical sector, despite both companies posting respectable financial results.

Market Skepticism Trumps Earnings Quality

The stock price weakness that caused both firms to underperform contradicts what appeared on the surface as decent earnings reports. While technology and precious metals surged higher, pharmaceutical investors seemed unconvinced. Merck logged a 5% bump in fourth-quarter global sales to $16.4 billion (4% adjusted for currency), with annual revenue exceeding $65 billion. Pfizer reported 2025 full-year revenue of approximately $63 billion, down 2% year-over-year. Both companies demonstrated operational discipline through adjusted earnings management, yet the market still penalized them, suggesting deeper concerns about the industry’s trajectory and competitive pressures.

Merck’s Oncology Fortress Faces Inevitable Cracks

Oncology remains the foundation of Merck’s business model, with Keytruda commanding nearly half of total revenue at $32 billion annually—a 7% increase for the year. The immunotherapy standout has been transformative for the company’s portfolio. However, this concentration creates vulnerability. Merck faces the prospect of Keytruda eventually losing patent protection later this decade, a cliff that already weighs on investor sentiment and explains some of the stock’s underperformance relative to market indices.

To mitigate this future headwind, Merck is banking on its newer therapeutic arsenal. Winrevair, a hypertension treatment, generated $1.4 billion in its inaugural year, while the pneumococcal vaccine Capvaxix contributed just under $800 million in first-year sales. The Animal Health division also fired on all cylinders, with sales climbing 8% to $6.4 billion. Management’s 2026 revenue guidance of roughly $66 billion suggests confidence in maintaining current run rates, though the market appears to be discounting earlier-stage product contributions.

Pfizer Navigates Patent Losses While Pivoting to Oncology

Pfizer’s revenue trajectory tells a different but equally cautious story. The 2% revenue decline to $63 billion masks an interesting strategic reorientation toward higher-margin oncology products. Padcev and Lorbrena have helped stabilize results as older blockbusters face generic erosion. The company achieved a 4% increase in adjusted earnings per share to $3.22, demonstrating that margin expansion can partially offset top-line pressure—yet the stock still continued to underperform, suggesting this tactical improvement isn’t enough to alter investor perception.

For 2026, Pfizer maintained prior guidance with revenue projected between $59.5 billion and $62.5 billion, and adjusted EPS in the $2.80 to $3.00 range. The company is actively addressing future growth through approximately 20 pivotal clinical trials launching this year, betting that genuine innovation will reignite investor enthusiasm. However, patent cliffs and pricing headwinds remain formidable obstacles.

The Broader Industry Challenge

What emerges from this earnings cycle is a pharmaceutical industry at an inflection point. Both Merck and Pfizer underperform the market not because they stumbled operationally, but because investors are skeptical about whether existing pipelines and emerging products can sustainably offset patent expirations and reimbursement pressure. Large-cap pharma continues to navigate transitions methodically—generating steady cash flows and advancing new therapies—but the market demands more dramatic catalysts. Until genuinely breakthrough therapies demonstrate transformative impact or major M&A reshapes portfolios, the sector’s relative underperformance may well persist, keeping investor attention elsewhere.